Nanox Imaging Ltd. (NASDAQ: NNOX) announced that its subsidiary, Nanox AI Ltd., has entered into a distribution agreement with Technologic s.r.l., an Italian company affiliated with Tecnologie Avanzate, to commercialize its AI-powered bone health solution, HealthOST, in Italy. The agreement is intended to expand Nanox AI’s commercial presence in the Italian market by leveraging Technologic’s experience and local market knowledge.
HealthOST analyzes eligible routine CT scans to provide qualitative and quantitative assessments of the spine, helping clinicians identify patients who may benefit from further evaluation for musculoskeletal conditions such as osteoporosis. The distribution deal marks a step in Nanox’s strategy to drive the transition to preventive health care through an integrated medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The company’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging; Nanox.CLOUD, a cloud-based platform for secure data management and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts; and Nanox Health IT, which delivers RIS, PACS, AI, dictation, and secure infrastructure solutions.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. The latest news and updates relating to NNOX are available in the company’s newsroom at http://ibn.fm/NNOX.
The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit www.BioMedWire.com.
